<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110898</url>
  </required_header>
  <id_info>
    <org_study_id>HYP 005-21</org_study_id>
    <nct_id>NCT05110898</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.</brief_title>
  <acronym>OLINDA</acronym>
  <official_title>Randomized, Single-Blind, Multicenter, Phase III, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainfarma Industria Química e Farmacêutica S/A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainfarma Industria Química e Farmacêutica S/A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III clinical trial, multicenter of non-inferiority, randomized, single-blind evaluation&#xD;
      of fixed-dose combination of olmesartan + indapamide compared to the isolated drugs in the&#xD;
      treatment of hypertension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed for the treatment of essential hypertension. It is performed in&#xD;
      participants of both sexes, over 18 years of age, who have essential hypertension with&#xD;
      diastolic blood pressure between 90 mmHg and 110 mmHg.&#xD;
&#xD;
      The rationale for studying the fixed dose combination is the possibility to enhance&#xD;
      compliance and simplify treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2022</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of fixed dose association of olmesartan + indapamide compared to the isolated drugs in the treatment of hypertension.</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>To evaluate the non-inferiority of the fixed dose association of olmesartan + indapamide to the isolated drugs in the change of the diastolic blood pressure from baseline to 12 week endpoint through Ambulatory Blood Pressure Monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure Control</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Proportion of participants achieving a diastolic blood pressure below 90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure Control</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Proportion of participants achieving a systolic blood pressure below 140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of systolic and diastolic treatment response</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Proportion of participants achieving a systolic blood pressure reduction greater than 20 mmHg and a diastolic blood pressure reduction greater than 10 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic and diastolic blood pressure variation by ABPM exam</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Systolic and diastolic blood pressure variation by ABPM examination from the baseline period compared to the result after 12 weeks of treatment;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients responses to the treatment satisfaction questionnaire</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Patients responses to a questionnaire regarding if they are satisfied with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and occurrence of adverse events (AEs) during the study period.</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Tolerability and occurrence of adverse events (AEs) during the study period in both study arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypertension,Essential</condition>
  <arm_group>
    <arm_group_label>Fixed-dose Olmesartan 20mg/40 mg + Indapamide 1,5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg</intervention_name>
    <description>Fixed-dose of Olmesartan 20mg or 40 mg + Indapamide 1,5 mg oral administration, once a day for 12 weeks. Initially, the participant will be treated with Olmesartan 20mg + Indapamide 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose will be changed to fixed dose of Olmesartan 40 mg + Indapamide 1,5 mg.</description>
    <arm_group_label>Fixed-dose Olmesartan 20mg/40 mg + Indapamide 1,5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)</intervention_name>
    <description>Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg) oral administration, once a day for 12 weeks. Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg. If after 6 weeks the diastolic blood pressure is above 90 mmHg, the dose of Benicar® (olmesartan) will be changed to 40 mg.</description>
    <arm_group_label>Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have signed the informed consent form;&#xD;
&#xD;
          -  Participants of both genders aged ≥ 18 years;&#xD;
&#xD;
          -  Essential hypertension based on a Diastolic Blood Pressure (DBP) &gt; 90 mmHg and &lt; 110&#xD;
             mmHg;&#xD;
&#xD;
          -  Patients with no treatment or on antihypertensive therapy taking up to two&#xD;
             anti-hypertensives;&#xD;
&#xD;
          -  Possibility of discontinuing previous antihypertensive medication during the washout&#xD;
             period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Essential hypertension based on a Diastolic Blood Pressure (DBP) ≥ 110mmHg and&#xD;
             Systolic Blood Pressure (SBP) ≥ 180 mmHg;&#xD;
&#xD;
          -  Secondary hypertension;&#xD;
&#xD;
          -  Participants with Body Mass Index (BMI) &gt; 35 Kg/m2;&#xD;
&#xD;
          -  Non-controlled types 1 and 2 diabetes mellitus (HbA1 &gt; 8,5%);&#xD;
&#xD;
          -  Myocardial infarction, coronary surgery or coronary angioplasty with or without stent&#xD;
             placement, in the last 6 months;&#xD;
&#xD;
          -  Unstable angina;&#xD;
&#xD;
          -  Participants with coronary heart disease taking beta-blockers;&#xD;
&#xD;
          -  Clinically manifest heart failure;&#xD;
&#xD;
          -  History of cardiac arrhythmia;&#xD;
&#xD;
          -  Moderate and severe heart valve disease;&#xD;
&#xD;
          -  Stroke or transient ischemic attack in the last 6 months;&#xD;
&#xD;
          -  Chronic disease of any nature that contraindicates the participant's participation&#xD;
             according to the investigator's judgment, in particular renal failure with glomerular&#xD;
             filtration rate &lt; 45 ml/min, serum potassium levels ≥ 5,5 mEq/L or ≤ 3,5 mEq/L,&#xD;
             hepatopathies, or SGOT, SGPT or bilirubin levels 3 times above the normal upper limit,&#xD;
             and blood dyscrasias;&#xD;
&#xD;
          -  Known allergies or contraindication to the use of the study medication components;&#xD;
&#xD;
          -  Female participants who are pregnant, breastfeeding or who want to become pregnant;&#xD;
&#xD;
          -  COVID-19 symptoms;&#xD;
&#xD;
          -  Post COVID-19 syndrome with cardiovascular impairment;&#xD;
&#xD;
          -  Subjects who have participated in other study within the 12 months prior to screening&#xD;
             (unless benefit is justified by the researcher).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>olmesartan</keyword>
  <keyword>olmesartan medoxomil</keyword>
  <keyword>indapamide</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Indapamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

